{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:41:54Z","timestamp":1778629314940,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.3816\/clm.2007.n.034","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T01:10:53Z","timestamp":1221095453000},"page":"507-513","source":"Crossref","is-referenced-by-count":18,"title":["Maintenance Therapy in Lymphoma"],"prefix":"10.3816","volume":"7","author":[{"given":"Ronald","family":"Mihelic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2007.n.034_bib1","first-page":"75","article-title":"Natural history of and therapy for the indolent non-Hodgkin's lymphomas","volume":"20","author":"Horning","year":"1993","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2007.n.034_bib2","first-page":"40","article-title":"Treatment options for newly diagnosed patients with adult acute lymphoblastic leukemia","volume":"3","author":"Lamanna","year":"2004","journal-title":"Curr Hematol Rep"},{"key":"10.3816\/CLM.2007.n.034_bib3","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1200\/JCO.2001.19.11.2927","volume":"19","author":"Sweetenham","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.n.034_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1054\/bjoc.2001.1822","article-title":"A randomized controlled trial to evaluate the role of interferon as Initials and maintenance therapy in patients with follicular lymphoma","volume":"85","author":"Rohatiner","year":"2001","journal-title":"Br J Cancer"},{"key":"10.3816\/CLM.2007.n.034_bib5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002371-200101000-00007","article-title":"Meta-analysis to assess the efficacy of interferon-alpha in patients with follicular non-Hodgkin's lymphoma","volume":"24","author":"Allen","year":"2001","journal-title":"J Immunother"},{"key":"10.3816\/CLM.2007.n.034_bib6","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1200\/JCO.2000.18.10.2010","article-title":"Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809","volume":"18","author":"Fisher","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.n.034_bib7","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1034\/j.1600-0609.2001.00272.x","article-title":"Interferon alfa 2b as maintenance therapy in poor risk diffuse large B-cell lymphoma in complete remission after intensive CHOP-BLEO regimens","volume":"66","author":"Aviles","year":"2001","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2007.n.034_bib8","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1089\/106161299320280","article-title":"Interferon as maintenance therapy in refractory malignant lymphoma","volume":"8","author":"Aviles","year":"1999","journal-title":"J Hematother"},{"key":"10.3816\/CLM.2007.n.034_bib9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3109\/10428190009054885","article-title":"A prospective randomized study of Chop versus Chop plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 Study","volume":"40","author":"Giles","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2007.n.034_bib10","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.n.034_bib11","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma\u2013a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.n.034_bib12","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.n.034_bib13","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/annonc\/mdi320","volume":"16","author":"Ghielmini","year":"2005","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2007.n.034_bib14","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/299778a0","article-title":"Immunoregulation by gamma-interferon?","volume":"299","author":"Basham","year":"1982","journal-title":"Nature"},{"key":"10.3816\/CLM.2007.n.034_bib15","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1073\/pnas.79.10.3265","article-title":"Interferon increases HLA synthesis in melanoma cells: interferon-resistant and -sensitive cell lines","volume":"79","author":"Basham","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CLM.2007.n.034_bib16","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1073\/pnas.75.12.6215","article-title":"Enhanced expression of beta2-microglobulin and HLA antigens on human lymphoid cells by interferon","volume":"75","author":"Heron","year":"1978","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CLM.2007.n.034_bib17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0268-960X(97)90019-9","article-title":"Role of alpha interferon in multiple myeloma","volume":"11","author":"Joshua","year":"1997","journal-title":"Blood Rev"},{"key":"10.3816\/CLM.2007.n.034_bib18","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.4049\/jimmunol.157.9.4100","article-title":"In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine","volume":"157","author":"D'Cunha","year":"1996","journal-title":"J Immunol"},{"key":"10.3816\/CLM.2007.n.034_bib19","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4161\/cbt.2.4.425","article-title":"Signal transduction and myeloma: new targets, new hope","volume":"2","author":"Lonial","year":"2003","journal-title":"Cancer Biol Ther"},{"key":"10.3816\/CLM.2007.n.034_bib20","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/296754a0","article-title":"A differentiation factor required for the expression of cytotoxic T-cell function","volume":"296","author":"Raulet","year":"1982","journal-title":"Nature"},{"issue":"6 suppl","key":"10.3816\/CLM.2007.n.034_bib21","doi-asserted-by":"crossref","first-page":"85s","DOI":"10.1111\/1523-1747.ep12874809","article-title":"Actions of TNF and IFNgamma on angiogenesis in vitro","volume":"95","author":"Sato","year":"1990","journal-title":"J Invest Dermatol"},{"key":"10.3816\/CLM.2007.n.034_bib22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0008-8749(88)90109-8","article-title":"Effects of interferon-gamma on the activation of human T lymphocytes","volume":"111","author":"Siegel","year":"1988","journal-title":"Cell Immunol"},{"key":"10.3816\/CLM.2007.n.034_bib23","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJM198411013111803","article-title":"Treatment of advanced non Hodgkin's lymphoma with recombinant leukocyte A interferon","volume":"311","author":"Foon","year":"1984","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2007.n.034_bib24","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1200\/JCO.2005.06.146","article-title":"Meta-analysis to evaluate the role of interferon in follicular lymphoma","volume":"23","author":"Rohatiner","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.n.034_bib25","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1200\/JCO.1998.16.4.1538","article-title":"Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization","volume":"16","author":"Arranz","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.n.034_bib26","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.264.65.1","article-title":"Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis","volume":"65","author":"Jazirehi","year":"2005","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2007.n.034_bib27","doi-asserted-by":"crossref","first-page":"8114","DOI":"10.1038\/sj.onc.1208954","article-title":"Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis","volume":"24","author":"Vega","year":"2005","journal-title":"Oncogene"},{"key":"10.3816\/CLM.2007.n.034_bib28","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.n.034_bib29","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.n.034_bib30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2007.n.034_bib31","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the RCHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.n.034_bib32","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma","volume":"9","author":"Berinstein","year":"1998","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2007.n.034_bib33","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1200\/JCO.2005.12.171","article-title":"Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders","volume":"23","author":"Gordan","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.n.034_bib34","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.n.034_bib35","doi-asserted-by":"crossref","first-page":"106a","DOI":"10.1182\/blood.V106.11.349.349","article-title":"Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B","volume":"106","author":"Hochster","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.n.034_bib36","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin's lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III Intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.n.034_bib37","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.n.034_bib38","first-page":"40a","article-title":"Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): an update","volume":"104","author":"Habermann","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.n.034_bib39","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","article-title":"Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"23","author":"Ghielmini","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.n.034_bib40","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1093\/annonc\/mdl127","article-title":"Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network","volume":"17","author":"Kahl","year":"2006","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2007.n.034_bib41","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.n.034_bib42","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.n.034_bib43","first-page":"276b","article-title":"Safety and tolerability of the combination of interleukin-2 (rIL-2) and rituximab in patients with refractory\/relapsed follicular non Hodgkin lymphoma. Preliminary data from the Pearl study","volume":"106","author":"Diaz","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.n.034_bib44","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1080\/17402520500182329","article-title":"Concurrent administration of granulocyte colony-stimulating factor or granulocytemonocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model","volume":"46","author":"Hernandez-Ilizaliturri","year":"2005","journal-title":"Leuk Lymphoma"},{"issue":"2 suppl","key":"10.3816\/CLM.2007.n.034_bib45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/sonc.2002.32747","article-title":"Beyond immunochemotherapy: combinations of rituximab with cytokines interferon-alpha2a and granulocyte colony stimulating factor [corrected]","volume":"29","author":"Kimby","year":"2002","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2007.n.034_bib46","doi-asserted-by":"crossref","first-page":"41a","DOI":"10.1182\/blood.V104.11.132.132","article-title":"Impact of course of therapy on response rate and duration with the Bexxar\u00ae therapeutic regimen (tositumomab and iodine I 131 tositumomab) and with chemotherapy","volume":"104","author":"Leonard","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.n.034_bib47","doi-asserted-by":"crossref","first-page":"107a","DOI":"10.1182\/blood.V106.11.352.352","article-title":"An update of a phase II trial of CHOP followed by tositumomab\/iodine I-131 tositumomab (Bexxar\u00ae) for front-line treatment of advanced stage, follicular lymphoma: Southwest Oncology Group Protocol 9911","volume":"106","author":"Press","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.n.034_bib48","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1200\/JCO.2006.09.3146","article-title":"Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"25","author":"Robertson","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011700981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011700981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T22:10:58Z","timestamp":1738361458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011700981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S1557919011700981"],"URL":"https:\/\/doi.org\/10.3816\/clm.2007.n.034","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}